$LMDX News

Last published 2y ago

2y agoLMDXLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thGlobeNewswireLONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be
2y agoLMDXLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheGlobeNewswireLONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its
3y agoLMDXLumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to AppealGlobeNewswireLONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock
3y agoLMDXLumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening HubGlobeNewswireMade possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club – Everton in the Community – the Liverpool-based hub will provide significant support for
3y agoLMDXLumiraDx Limited (LMDX) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoLMDXLumiraDx Reports Second Quarter 2023 ResultsGlobeNewswireLONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.
3y agoLMDXLumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24GlobeNewswireLONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August
3y agoLMDXLumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and TestsGlobeNewswirePartnership between LumiraDx and Axonlab will allow Axonlab to sell the unique LumiraDx Point of Care testing solution and give LumiraDx the ability to expand the reach of the LumiraDx Platform and tests.The agreement
3y agoLMDXLumiraDx Submits First 510(k) Application to the FDA for COVID Ultra TestGlobeNewswireLONDON, June 30, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a leading innovator in diagnostic technologies, today announced the submission of its first 510(k) application to the U.S. Food and Drug
3y agoLMDXLumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV TestsGlobeNewswireLumiraDx SARS-CoV-2 Ag Ultra & SARS-CoV-2 Ag & RSV tests have been successfully validated by the Medicines and Healthcare products Regulatory Agency (MHRA) under the Coronavirus Test Device Approvals (CTDA)
3y agoLMDXLumiraDx Reports First Quarter 2023 ResultsGlobeNewswireLONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First
3y agoLMDXLumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16GlobeNewswireLONDON, May 09, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Tuesday, May 16th,
3y agoLMDXLumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireLONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification (the "Notification") from The Nasdaq Stock Market LLC that it is not in
3y agoLMDXLumiraDx Announces Strategic Refocus and Cost Restructuring ProgramGlobeNewswireLONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Restructuring Program
3y agoLMDXLumiraDx Reports Fourth Quarter and Full Year 2022 ResultsGlobeNewswireLONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended
3y agoLMDXLumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21GlobeNewswireLONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results
3y agoLMDXLumiraDx to Present at Raymond James Institutional Investors ConferenceGlobeNewswireLONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company") today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors
3y agoLMDXLumiraDx Regains Compliance with Nasdaq Continued Listing RequirementsGlobeNewswireLONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company") today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it has regained compliance
3y agoLMDXLumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular AssayGlobeNewswireLumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully validated by the UK Health Security Agency (UKHSA) under the Coronavirus Test
3y agoLMDXLumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UKGlobeNewswireRun on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick
3y agoLMDXLumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyGlobeNewswireLONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification (the "Notification") from The Nasdaq Stock Market LLC that it is not in
3y agoLMDXLumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis TestGlobeNewswireLONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced it has received $14.2M in grants from the Bill & Melinda Gates
3y agoLMDXLatest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing CentersGlobeNewswireWALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced findings from its second annual "Point of Care Diagnostics: A
3y agoLMDXLumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestPR NewswireNow Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers include GP offices and other community-based healthcare settingsLatest figures, released as part of World Diabetes Day,
3y agoLMDXLumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestGlobeNewswireEarly customers include GP offices and other community-based healthcare settingsLatest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly half are
4y agoLMDXLumiraDx Reports Third Quarter 2022 ResultsGlobeNewswireLONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the third quarter ended
4y agoLMDXLumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9GlobeNewswireLONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday,
4y agoLMDXLumiraDx Reports Second Quarter 2022 ResultsGlobeNewswireLONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second quarter ended June 30, 2022. Q2 2022 revenue of $4
4y agoLMDXLumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18GlobeNewswireLONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the r
4y agoLMDXLumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private PlacementPR NewswireLONDON, July 21, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.7
4y agoLMDXLumiraDx Announces Proposed Public Offering of Common SharesPR NewswireLONDON, July 19, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares. All of the shares in the p
4y agoLMDXLumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing SystemPR NewswireNext-generation antigen test system built on more than eight years of research and backed by industry leading microfluidic experts The Amira System includes the Amira Analyzer, Amira SARS-CoV-2 Ag test strips, swabs and sample preparation materials De
4y agoLMDXLumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR CompletePR NewswireLONDON, June 8, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete. Th
4y agoLMDXLumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer TestPR NewswireThe LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are designed for near-patient testing with connected results
4y agoLMDXLumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic PlatformPR NewswireRapid microfluidic immunofluorescence assay intended for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for developing diabetes The automated, quantitative fingerstick assay is run on
4y agoLMDXLumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag TestPR NewswireLONDON, May 20, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use List
4y agoLMDXLumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE MarkingPR NewswireResults in just 5 minutes from sample application, aids in fast clinical decision-making at point of care (POC), helping to inform treatment decisions and prevent the further spread of infection, while also increasing testing throughput Run on the mult
4y agoLMDXLumiraDx Reports First Quarter 2022 ResultsPR NewswireStrong Growth in Instruments Delivered to Customers and Continued Innovation on our Platform LONDON, May 11, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and
4y agoLMDXLumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11PR NewswireLONDON, April 29, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022. On the day of the release, Lumi
4y agoLMDXLumiraDx Reports Fourth Quarter and Full Year 2021 ResultsPR NewswireLONDON, March 10, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2021.
4y agoLMDXLumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10PR NewswireLONDON, March 3, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022. On the day
4y agoLMDXLumiraDx Announces Pricing of $56.5 Million Convertible Notes OfferingPR NewswireLONDON, March 1, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX) announced today that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase f
4y agoLMDXLumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron VariantPR NewswireLONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron
4y agoLMDXLumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen TestPR NewswireLONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.
4y agoLMDXLumiraDx CRP Test Achieves CE MarkingPR NewswireLONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking. The LumiraDx CRP Test is a small, portable, fully automated, mic
4y agoLMDXLumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE MarkingPR NewswireLONDON, Dec. 23, 2021 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly ver
4y agoLMDXLumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR CompletePR NewswireLONDON, Dec. 15, 2021 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV
4y agoLMDXAudere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test KitBusiness WireEnables CLIA-certified laboratories using HealthPulse@home authorized labeling instructions to offer new test kits under Audere's EUA Audere, a digital health nonprofit developing solutions to improve global health, announced that it has received an
4y agoLMDXFDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing SolutionsPR NewswireLONDON, Dec. 1, 2021 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR Complete, a rapid, nucleic acid amplification technolog
5y agoLMDXLumiraDx Reports Third Quarter 2021 Financial ResultsPR NewswireLONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021.